SCHEMBL770681

SCHEMBL770681

CCOC(=O)CCCC(=O)N1CCC2CCCC=C2C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TSHR P16473 4/20 0.41
ALDH1A1 P00352 6/20 0.41
NPC1 O15118 3/20 0.41
NAMPT P43490 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPK10 P53779 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
FDFT1 P37268 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770912 0.93 TSHR (0.48) RAB9AL3MBTL1TSHRALDH1A1NPC1
SCHEMBL769789 0.88 NPC1 (0.42) TSHRALDH1A1NPC1NAMPTLMNA
SCHEMBL770338 0.86 GLA (0.42) RAB9AALDH1A1NPC1NAMPTMEN1
SCHEMBL770401 0.85 LMNA (0.39) L3MBTL1ALDH1A1NPC1NAMPTLMNA
SCHEMBL769712 0.83 NPC1 (0.57) RAB9AALDH1A1NPC1LMNAPOLB
SCHEMBL770997 0.83 ATM (0.47) RAB9AL3MBTL1ALDH1A1NPC1TDP1
SCHEMBL770381 0.83 ITGB3 (0.41) TSHRALDH1A1NPC1LMNAPOLB
SCHEMBL771656 0.83 MAPK1 (0.36) ALDH1A1NPC1NAMPTLMNAPOLB
SCHEMBL771078 0.82 NPC1 (0.42) TSHRALDH1A1NPC1NAMPTLMNA
SCHEMBL771609 0.82 LMNA (0.36) L3MBTL1ALDH1A1NPC1NAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2187/4885L3MBTL1 4097/4885TSHR 3844/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2217/4885L3MBTL1 4090/4885TSHR 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.